Effect of Tocilizumab on "Ventilator Free Days" Composite Outcome in SARS-CoV-2 Patients: A Retrospective Competing Risk Analysis.
Ahmed F MadyBasheer AbdulrahmanShahzad A MumtazMohammed A Al-OdatAhmed KuhailRehab AltoraifiRayan AlshaeAbdulrahman M AlharthyDimitrios KarakitsosWaleed Th AletrebyPublished in: Romanian journal of anaesthesia and intensive care (2023)
Tocilizumab may improve the composite outcome of ventilator-free days at day 28 among mechanically ventilated SARS-CoV-2 patients; it is associated with significantly longer actual ventilator-free periods, and insignificantly lower mortality and higher superinfection.
Keyphrases
- sars cov
- end stage renal disease
- ejection fraction
- acute respiratory distress syndrome
- newly diagnosed
- rheumatoid arthritis
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- mechanical ventilation
- type diabetes
- risk factors
- cardiovascular disease
- respiratory syndrome coronavirus
- cardiovascular events
- coronary artery disease
- coronavirus disease
- disease activity